AR-SA">B-cell depletion and recovery after treatment with the anti-CD20 monoclonal antibody rituximab in patients with posttransplant lymphoproliferative disorders (PT-LPD).

被引：0
|
作者：
Grefer, J
Oertel, SH
Hummel, M
Serke, S
Reinke, P
Jonas, S
Anagnostopoulos, I
Arnold, R
Dörken, B
Riess, H
机构：
[1] Humboldt Univ, Klinikum Rudolf Virchow, Charite, Berlin, Germany
[2] Deutsches Herzzentrum, Berlin, Germany
[3] Free Univ Berlin, D-1000 Berlin, Germany
来源：
BLOOD | 2001年 / 98卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4693
引用
收藏
页码：242B / 242B
页数：1
相关论文
共 50 条
  • [1] B-cell depletion and recovery after treatment with the anti-CD20 monoclonal antibody rituximab in patients with posttransplant lymphoproliferative disorders (PT-LPD).
    Grefer, J
    Oertel, SH
    Hummel, M
    Serke, S
    Reinke, P
    Jonas, S
    Anagnostopoulos, L
    Arnold, R
    Dörken, B
    Riess, H
    BLOOD, 2001, 98 (11) : 132A - 132A
  • [2] B-cell depletion in patients with multiple myeloma with the anti-CD20 monoclonal antibody rituximab after high dose therapy
    Witzens, M
    Gemmel, C
    Moos, M
    Goldschmidt, H
    Ho, AD
    BONE MARROW TRANSPLANTATION, 1999, 23 : S141 - S141
  • [3] Rituximab chimeric anti-CD20 monoclonal antibody treatment for refractory hemolytic anemia in patients with lymphoproliferative disorders
    Trapè, G
    Fianchi, L
    Lai, M
    Laurenti, L
    Piscitelli, R
    Leone, G
    Pagano, L
    HAEMATOLOGICA, 2003, 88 (02) : 223 - 225
  • [4] A Phase I trial of B-cell depletion with anti-CD20 monoclonal antibody (rituximab) in the treatment of systemic lupus erythematosus
    R Eisenberg
    D Albert
    J Stansberry
    D Tsai
    S Kolasinski
    S Khan
    Arthritis Res Ther, 5
  • [5] A Phase I trial of B-cell depletion with anti-CD20 monoclonal antibody (rituximab) in the treatment of systemic lupus erythematosus
    Eisenberg, R
    Albert, D
    Stansberry, J
    Tsai, D
    Kolasinski, S
    Khan, S
    ARTHRITIS RESEARCH & THERAPY, 2003, 5 (Suppl 3) : S9 - S10
  • [6] Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with clonal lymphoproliferative disorders after orthotopic liver transplantation: a report of three cases
    Zompi, S
    Tulliez, M
    Conti, F
    Leblond, V
    Gaulard, P
    Blanche, P
    Durand, F
    Ghandi, D
    Dreyfus, F
    Louvel, A
    Calmus, Y
    Bouscary, D
    JOURNAL OF HEPATOLOGY, 2000, 32 (03) : 521 - 527
  • [7] Treatment of posttransplant lymphoproliferative disorder with the anti-CD20 monoclonal antibody rituximab alone in an adult after liver transplantation - A new drug in therapy of patients with posttransplant lymphoproliferative disorder after solid organ transplantation?
    Oertel, SHK
    Anagnostopoulos, I
    Bechstein, WO
    Liehr, H
    Riess, HB
    TRANSPLANTATION, 2000, 69 (03) : 430 - 432
  • [8] Ofatumumab, a Novel Anti-CD20 Monoclonal Antibody for the Treatment of B-Cell Malignancies
    Cheson, Bruce D.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (21) : 3525 - 3530
  • [9] Anti-CD20 monoclonal antibody as a new treatment modality for B-cell lymphoma
    Hotta, T
    ACTA HISTOCHEMICA ET CYTOCHEMICA, 2002, 35 (04) : 275 - 279
  • [10] Successful treatment of B-cell prolymphocytic leukemia with monoclonal anti-CD20 antibody
    Abou Mourad, Y
    Taber, A
    Chehal, A
    Shamseddine, A
    ANNALS OF HEMATOLOGY, 2004, 83 (05) : 319 - 321
12345